Top Markets
Coin of the day
Q BioMed Inc. Q BioMed Inc.

Q BioMed Inc.

QBIO
株式のランク #41615
Q BioMed Inc. functions as a biomedical accelerator and developer, actively... Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer. Additionally, Q BioMed is advancing a pipeline of therapeutic candidates, including Man-01, a pre-clinical compound aimed at primary open-angle glaucoma; QBM-001, intended for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, which targets liver cancer. The company also collaborates with Mannin Research Inc. on the development of treatments for conditions such as acute respiratory distress syndrome, glaucoma, and various kidney diseases. Incorporated in New York, New York, in 2013, the entity was initially named ISMO Tech Solutions, Inc. before adopting its current name, Q BioMed Inc., in July 2015.
株価
$0.0001
最終同期: 2026-04-02
時価総額
$14.51K
変化(1日)
0.00%
変化(1年)
9,900.00%
US
取引 Q BioMed Inc. (QBIO)

カテゴリー

Q BioMed Inc.(QBIO)の配当利回りの履歴
Q BioMed Inc.(銘柄コード: QBIO)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Q BioMed Inc.(QBIO)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)